



CSL Seqirus Portfolio Coding and Billing Guide

2024-2025

Please see Important Safety Information on pages 11-13 and accompanying full US Prescribing Information for each product.

For US Healthcare Professional Use Only

Find more resources at flu360.com

CSL Segirus

Using this guide

Consider this your go-to comprehensive resource for all 3 CSL Seqirus influenza vaccines to ensure the use of appropriate CPT codes, check recent NDCs, code appropriately based on payer, and more. You can also find individual vaccine guides at flu360.com. When it comes to coding and billing for CSL Seqirus vaccines, we've got you covered.

- 3....Code for the CSL Seqirus vaccine administered
- 4....Current NDCs
- 5....Code for the administration service
- 6 FLUAD® (Influenza Vaccine, Adjuvanted)
- 7FLUCELVAX® (Influenza Vaccine)
- 8....AFLURIA® (Influenza Vaccine)
- 9....Commonly asked questions

CPT=Current Procedural Terminology NDCs=National Drug Codes

Code for the CSL Seqirus vaccine administered

CPT codes indicate the influenza vaccine administered. Be sure to use the appropriate CPT code to receive proper payment.

FLUAD, the first and only adjuvanted seasonal influenza vaccine for adults 65 years and older, uses CPT code 90653.^{1,2}

FLUCELVAX, an innovative cell-based vaccine for people 6 months and older, has unique CPT code 90661.^{1,3}

CSL Seqirus Vaccine	Presentation/	Age	Vaccine Product	2024-2025	2024-2025 NDC	CVX	MVX
Product Description	Dose	Indication	CPT Code	NDC Carton	Unit-of-Use	Code*	Code
FLUAD® (Influenza Vaccine, Adjuvanted)	Pre-filled syringe 0.5 mL	65 years and older	90653	70461-024-03	70461-024-04	168	SEQ

90653=Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use

FLUCELVAX®	Pre-filled syringe 0.5 mL	6 months and older	90661	70461-654-03	70461-654-04	153	SEQ
(Influenza Vaccine)	Multi-dose vial 5 mL	6 months and older	90661	70461-554-10	70461-554-11	320	SEQ

90661=Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5-mL dosage, for intramuscular use

	Pre-filled syringe 0.5 mL	36 months and older	90656	33332-024-03	33332-024-04	140	SEQ
AFLURIA® (Influenza Vaccine)	Multi-dose vial [†] 5 mL	6 through 35 months	90657 (0.25-mL dose)	33332-124-10	33332-124-11	141	850
		36 months and older	90658 (0.5-mL dose)	33332-124-10	33332-124-11	141	SEQ

90656=Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5-mL dosage, for intramuscular use 90657=Influenza virus vaccine, trivalent (IIV3), split virus, 0.25-mL dosage, for intramuscular use 90658=Influenza virus vaccine, trivalent (IIV3), split virus, 0.5-mL dosage, for intramuscular use

^{*}CVX=vaccine administered code indicates which product was used and is used in combination with the manufacturer (MVX) code.

[†]The number of needle punctures should not exceed 20 per multi-dose vial.

National Drug Codes (NDCs) change each year for influenza vaccines

If your payer requires NDCs, confirm that you are using this year's NDCs, as they change each year for influenza vaccines. The NDCs for the 2024–2025 influenza season are listed in the grid to the left. TriCare, some Medicaid agencies, commercial payers, and Medicare Administrative Contractors (MACs) require the use of an 11-digit NDC in addition to the CPT code on claims for influenza vaccines (eg, FLUAD-70461-0024-04; the red number shows where the additional zero needs to be added to make an 11-digit format and is the same for all of our vaccines). Note there are two different NDCs, carton or syringe/vial (unit-of-use), per the US Food and Drug Administration (FDA). Record the NDC on the syringe/vial (unit-of-use) in the patient's record, as per the standard procedure in your practice. Medicare, TriCare, and many commercial payers use the carton NDC for claims processing/reimbursement. For assistance with NDCs, call flu360 Customer Service at (855) 358-8966, option 2.

DISCLAIMER: The coding and billing information contained in this document is presented as a resource and guide to coding and billing for FLUAD (Influenza Vaccine, Adjuvanted), FLUCELVAX (Influenza Vaccine), and AFLURIA (Influenza Vaccine). Coding and billing information is gathered from several sources and is subject to change without notice. While every effort is made to ensure the accuracy of this information, appropriate coding and billing for healthcare services are the provider's responsibility and should always be based on the patient's clinical condition, services provided, and payer guidelines.

Code for the administration service

The method of administration for CSL Seqirus vaccines should be reported in addition to the vaccine product code. Use the appropriate immunization administration code based on the service provided and documented in the medical record. The following CPT codes are for vaccines administered via injection to individuals.⁴

CPT Code	Description
90460	Immunization administration through 18 years of age via any route of administration with counseling by physician or other qualified healthcare professional; first or only component of each vaccine or toxoid administered
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)
90472	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)

Note: Medicare requires use of Healthcare Common Procedure Coding System (HCPCS) code G0008 for the preventive administration of an influenza vaccine. HCPCS code G0008 must be used when billing Medicare instead of the administration CPT codes, regardless of the patient age or provider counseling. Other payers may require the use of HCPCS G0008; check with your payer for preferred administration code.⁵

HCPCS Code	Description
G0008	Seasonal influenza virus vaccine administration

Influenza vaccine International Classification of Diseases, Tenth Revision diagnosis codes

Below is a suggested *International Classification of Diseases, Tenth Revision* (ICD-10) diagnosis code that may be appropriate when submitting claims for CSL Seqirus vaccines and their administration. The code should be linked to both the vaccine and administration codes.⁵

ICD-10 Code	Description
Z23	Encounter for immunization

Modifier 25 is used to denote when a patient receives a significant, separately identifiable Evaluation and Management (E/M) service by the same physician on the same day of the procedure or other service. The E/M service may be prompted by the symptom or condition for which the procedure and/or service was provided, so different diagnoses are not required for reporting the E/M services on the same date.

Note: This modifier is not used to report an E/M service that resulted in a decision to perform surgery; see modifier 57. For significant, separately identifiable, non-E/M services on the same day, see modifier 59.6


For any reimbursement-related questions, call flu360 Customer Service at (855) 358-8966, option 2.

Refer to the following pages for coding and billing information specific to CSL Segirus vaccines.


Visit flu360.com for additional resources and information on coding and billing for CSL Segirus flu vaccines.

FLUAD® (Influenza Vaccine, Adjuvanted) administered to a patient on Medicare





Sample Claim Form



R29.6=repeated falls

Z23=encounter for immunization

If required by payer, 11-digit NDC format using the carton NDC. If payer requires NDC, use the "N4" qualifier immediately followed by the 11-digit carton NDC, followed by the qualifier "ML" for milliliter and the quantity as shown in the shaded area

Refer back to the appropriate diagnosis code on each line, including the vaccine and the vaccine administration

99203=office or other outpatient visit of 30-44 minutes for the E&M of a new patient

25=modifier (See page 5: Code for the administration service)

90653=FLUAD

G0008=administration

FLUCELVAX® (Influenza Vaccine) administered at a problem-focused visit



J45.40=moderate persistent asthma, uncomplicated

Z23=encounter for immunization

If required by payer, 11-digit NDC format using the carton NDC. If payer requires NDC, use the "N4" qualifier immediately followed by the 11-digit carton NDC, followed by the qualifier "ML" for milliliter and the quantity as shown in the shaded area

Refer back to the appropriate diagnosis code on each line, including the vaccine and the vaccine administration

99212=office or other outpatient visit of 10-19 minutes for an established patient


25=modifier (See page 5: Code for the administration service)

90661=FLUCELVAX

90471=administration

A 34-year-old woman with a private health insurance plan is seen at the physician's office for evaluation of her asthmatic condition and related prescription refills. The physician recommends she receive an influenza vaccine and administers FLUCELVAX.^{1,3,5-7}

Sample Claim Form



AFLURIA® (Influenza Vaccine) administered at a well visit



Z00.00=encounter for general adult medical examination without abnormal findings

Z23=encounter for immunization

If required by payer, 11-digit NDC format using the carton NDC. If payer requires NDC, use the "N4" qualifier immediately followed by the 11-digit carton NDC, followed by the qualifier "ML" for milliliter and the quantity as shown in the shaded area

Refer back to the appropriate diagnosis code on each line, including the vaccine and the vaccine administration

99395=periodic comprehensive preventive medicine re-evaluation, established patient; 18-39 years


90656=AFLURIA

90471=administration

for a well visit and receives an influenza vaccination, AFLURIA.^{1,5-8}

A 28-year-old woman with a private health insurance plan is seen

Sample Claim Form



Commonly asked questions

When it comes to coding and billing, accuracy matters.

Q: What does the transition to trivalent influenza vaccines mean from a coding & billing perspective?

A: With the transition to trivalent influenza vaccines, it means that both CPT codes and NDC numbers will be changing as compared to last season. It is imperative you are using the correct trivalent CPT code along with the appropriate NDC number. These trivalent CPT codes have been in existence but have not been used in several years. It is critical to ensure that these trivalent CPT codes are loaded and active within your billing system prior to the start of your flu vaccination campaign.

Q: What is the age indication for FLUCELVAX® (Influenza Vaccine)?

A: As of October 2021, FLUCELVAX is approved for use in people 6 months of age and older.³ The billing CPT code for FLUCELVAX is CPT code 90661 for all presentations.

- Q: What has changed with the CDC Advisory Committee on Immunization Practices (ACIP) and influenza vaccine recommendations for adults 65 years and older?
- **A:** In June 2022, the ACIP voted 15–0 in favor of recommending specific influenza vaccines for adults 65+.9

The ACIP preferentially recommends adjuvanted or higher dose over standard-dose influenza vaccines.⁹

FLUAD® (Influenza Vaccine, Adjuvanted) is included as a preferentially recommended seasonal influenza vaccine for adults 65 years and older.9

Q: When will we know the Medicare reimbursement rates for the influenza vaccines for the next season? Where can I find the information?

A: The Medicare Part B payment allowances for seasonal influenza vaccines provided in the physician's office or clinic are based on 95% of the AWP as reflected in the published pricing compendia each year. You can locate this information by going to CMS.gov and typing "seasonal influenza vaccine reimbursement" into the search bar. All influenza vaccines will be listed on the CMS Medicare Fee for Service Vaccine pricing list by CPT code. Each flu season, CMS publishes the revised Medicare Part B fee for service vaccine pricing list for the flu season, typically by the end of August of each year. 10

Commonly asked questions

(continued)

- O: Where can I find Medicare's Part B Influenza Administration Rates for my locality?
- A: To see your specific locality payment rate when billing for influenza vaccine administration (HCPCS G0008) visit "Vaccine Pricing" on CMS.gov and open the following file: 2024 Locality-Adjusted Rates for Influenza. 10,11
- Q: How does Medicare work in regard to flu shots given prior to them updating their fee schedule?
- A: Immunizations performed and billed prior to the fee schedule update will be paid from the prior fee schedule. Medicare updates its payment rates retroactive to August 1 and is required to reprocess any previously processed and paid claims for the current flu season that were paid using influenza vaccine payment allowances other than the allowances published in the influenza vaccine pricing website.
- Q: Which NDC should I use, the one on the box or the one on the actual vial of vaccine?
- A: Most, but not all, payers require an NDC number on an influenza vaccine claim. Most commercial payers, TriCare, and some state Medicaid agencies require the carton NDC for claims processing/reimbursement. If you are not sure, check with your payer to confirm their preferred NDC, either carton or unit-of-use. If you need assistance, call **flu360 Customer Service** at (855) 358-8966, option 2.

- Q: When a pharmacy is submitting a prescription claim for an influenza vaccine to the pharmacy benefit using the National Council for Prescription Drug Program (NCPDP) standard, what should a pharmacy submit in the Days Supply field?
- A: When billing for a vaccine, it is recommended that the dispenser submit a value of 1 in the Days Supply field. 12
- Q: When a pharmacy is submitting a prescription claim for an influenza vaccine to the pharmacy using the NCPDP standard, what additional steps need to be taken to account for the administration portion?
- A: Pharmacies should submit an "MA" (Medication Administered) in the Professional Service Code (440-E5) and submit an amount in the Incentive Amount Submitted (438-E3) to request reimbursement for the administration of an influenza vaccine.12
- Q: What reimbursement services are offered via flu360 Customer Service?
- A: We assist healthcare providers in understanding the coding, coverage, and reimbursement requirements for all of CSL Segirus' influenza vaccines. This includes verifying a patient's insurance benefits, confirming payer requirements for coding, and, if needed, claims appeal support in the event of denied or underpaid claims

DISCLAIMER: The coding and billing information contained in this document is presented as a resource and guide to coding and billing for FLUAD (Influenza Vaccine, Adjuvanted), FLUCELVAX (Influenza Vaccine), and AFLURIA (Influenza Vaccine). Coding and billing information is gathered from several sources and is subject to change without notice. While every effort is made to ensure the accuracy of this information, appropriate coding and billing for healthcare services are the provider's responsibility and should always be based on the patient's clinical condition, services provided, and payer guidelines.



FLUAD® (Influenza Vaccine, Adjuvanted)

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

FLUAD is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is approved for use in adults 65 years of age and older.

This indication is approved under accelerated approval based on the immune response elicited by FLUAD. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Do not administer FLUAD to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or to a previous influenza vaccine.

WARNINGS AND PRECAUTIONS

If Guillain-Barré Syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUAD.

Syncope (fainting) may occur in association with administration of injectable vaccines including FLUAD. Procedures should be in place to avoid injury from fainting.

The immune response to FLUAD in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals.

Vaccination with FLUAD may not protect all vaccine recipients against influenza disease.

ADVERSE REACTIONS

The most common (≥10%) local and systemic adverse reactions in adults 65 years of age and older who received FLUAD were injection site pain (25%), injection site tenderness (21%), myalgia (15%), fatigue (13%) and headache (13%).

Other adverse events may occur.

To report SUSPECTED ADVERSE REACTIONS, contact CSL Segirus at 1-855-358-8966 or VAERS at 1-800-822-7967 and www.vaers.hhs.gov.

Before administration, please see the full US Prescribing Information for FLUAD.



FLUCELVAX[®] (Influenza Vaccine)

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

FLUCELVAX is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUCELVAX is approved for use in persons 6 months of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Do not administer FLUCELVAX to anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine.

WARNINGS AND PRECAUTIONS

If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUCELVAX should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUCELVAX.

Syncope (fainting) has been reported following vaccination with FLUCELVAX. Procedures should be in place to avoid injury from fainting.

After vaccination with FLUCELVAX, immunocompromised individuals, including those receiving immunosuppressive therapy, may have a reduced immune response.

Vaccination with FLUCELVAX may not protect all vaccine recipients against influenza disease.

ADVERSE REACTIONS

Data for FLUCELVAX QUADRIVALENT are relevant to FLUCELVAX because both vaccines are manufactured using the same process and have overlapping compositions.

In children 6 months through 3 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were tenderness (28%), erythema (26%), induration (17%) and ecchymosis (11%). The most common systemic adverse reactions were irritability (28%), sleepiness (27%), diarrhea (18%) and change of eating habits (17%).

In children 4 through 8 years of age who received FLUCELVAX, the most commonly reported local injection-site adverse reactions were pain (29%) and erythema (11%). The most common systemic adverse reaction was fatigue (10%).

In children and adolescents 9 through 17 years of age who received FLUCELVAX, the most commonly reported injection-site adverse reactions were pain (34%) and erythema (14%). The most common systemic adverse reactions were myalgia (15%) and headache (14%).

In adults 18 through 64 years of age who received FLUCELVAX, the most commonly reported injection-site adverse reactions were pain (28%) and erythema (13%). The most common systemic adverse reactions were headache (16%), fatigue (12%), myalgia (11%) and malaise (10%).

In adults ≥65 years who received FLUCELVAX the most commonly reported injection-site reaction was erythema (10%). The most common systemic adverse reactions were fatigue (11%), headache (10%) and malaise (10%).

Other adverse events may occur.

To report SUSPECTED ADVERSE REACTIONS, contact CSL Segirus at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Before administration, please see the full US Prescribing Information for FLUCELVAX.



AFLURIA® (Influenza Vaccine)

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

AFLURIA is an inactivated influenza vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine. AFLURIA is approved for use in persons 6 months of age and older

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Do not administer AFLURIA to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.

WARNINGS AND PRECAUTIONS

If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of AFLURIA.

If AFLURIA is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be diminished.

Vaccination with AFLURIA may not protect all individuals.

ADVERSE REACTIONS

Data for AFLURIA QUADRIVALENT are relevant to AFLURIA because both vaccines are manufactured using the same process and have overlapping compositions.

Administered by needle and syringe (AFLURIA QUADRIVALENT data):

In children 6 months through 35 months of age, the most commonly reported injection-site reactions were pain and redness (≥ 20%). The most common systemic adverse reactions were irritability ($\geq 30\%$), diarrhea and loss of appetite ($\geq 20\%$).

In children 36 through 59 months of age, the most commonly reported injection site reactions were pain (≥ 30%) and redness (≥ 20%). The most commonly reported systemic adverse reactions were malaise and fatigue, and diarrhea (≥ 10%).

In children 5 through 8 years, the most commonly reported injection-site adverse reactions were pain ($\geq 50\%$), redness and swelling ($\geq 10\%$). The most common systemic adverse reaction was headache (≥ 10%).

In children 9 through 17 years, the most commonly reported injection-site adverse reactions were pain (≥ 50%), redness and swelling (≥ 10%). The most common systemic adverse reactions were headache, myalgia, and malaise and fatique (≥ 10%).

In adults 18 through 64 years, the most commonly reported injection-site adverse reaction was pain (≥ 40%). The most common systemic adverse reactions were myalgia and headache (≥ 20%).

In adults 65 years of age and older, the most commonly reported injection-site adverse reaction was pain (≥ 20%). The most common systemic adverse reaction was myalgia (≥ 10%)

Administered by the PharmaJet Stratis Needle-Free Injection System:

In adults 18 through 64 years of age, the most commonly reported injection-site adverse reactions were tenderness (≥ 80%), swelling, pain, redness (≥ 60%), itching (≥ 20%) and bruising (≥ 10%). The most common systemic adverse reactions were myalgia, malaise (≥ 30%), and headache (≥ 20%).

Other adverse events may occur.

To report SUSPECTED ADVERSE REACTIONS, contact CSL Segirus at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Before administration, please see the full US Prescribing Information for AFLURIA.

Information on reimbursement is provided as a courtesy. Due to the rapidly changing nature of the law, Medicare payment policy, and/or reliance on information provided by outside sources, the information provided herein does not constitute a guarantee or warranty that reimbursement will be received or that the codes identified herein are or will remain applicable. This information is provided "as is" and without any other warranty or guarantee, expressed or implied, as to completeness or accuracy, or otherwise.

Providers must confirm or clarify coding and coverage from their respective payers, and are responsible for accurate reporting of products in accordance with particular payer requirements.

References: 1. Centers for Disease Control and Prevention. CPT codes mapped to CVX codes. Accessed March 8, 2024. https://www2a.cdc.gov/vaccines/iis/ iisstandards/vaccines.asp?rpt=cpt 2. FLUAD. Package insert. Segirus Inc. 3. FLUCELVAX. Package insert. Segirus Inc. 4. American Academy of Pediatrics. Coding for pediatric preventive care 2022. Accessed February 22, 2024. https://downloads.aap.org/AAP/PDF/Coding%20Preventive%20Care.pdf 5. Centers for Medicare & Medicaid Services. Flu shot & administration. Accessed March 8, 2024. https://www.cms.gov/Medicare/Prevention/PrevntionGenInfo/medicare-preventiveservices/MPS-QuickReferenceChart-1.html#FLU 6. American Medical Association. Current Procedural Terminology 2024 (Professional Edition). American Medical Association; 2023. 7. Centers for Disease Control and Prevention. ICD-10-CM tabular list of diseases and injuries. Accessed February 6, 2023. https://ftp.cdc.gov/ pub/Health Statistics/NCHS/Publications/ICD10CM/2022/icd10cm-tabular-2022-April-1.pdf 8. AFLURIA. Package insert. Seqirus Inc. 9. Centers for Disease Control and Prevention. ACIP Flu Meeting Update: Flu vaccines worked better than reported & ACIP recommends specific vaccines for seniors. Accessed May 7, 2024. https://www.cdc.gov/flu/spotlights/2021-2022/specific-vaccines-seniors.htm 10. Centers for Medicare & Medicaid Services. Vaccine pricing. Accessed May 7, 2024. https://www.cms.gov/medicare/payment/part-b-drugs/vaccine-pricing 11. Centers for Medicare & Medicaid Services. Physician Fee Schedule. Accessed May 7, 2024. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched 12. National Council for Prescription Drug Programs. Telecommunication version D and above questions, answers and editorial updates version 53. Accessed May 7, 2024. https://www.ncpdp.org/NCPDP/media/pdf/ Version-D-Questions-v53.pdf

flu360° pairs our portfolio of innovative influenza vaccines with the support you need







3 easy ordering methods:



Order online at **flu360.com**



Email customer service at **customerservice.us** @segirus.com



Contact your CSL Seqirus account manager about our portfolio of influenza vaccines and treatment

Questions?



Call flu360 Customer Service (855) 358-8966, option 2